Koichi Katsura

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

Yoshiaki Tomiyama, Yoshitaka Miyakawa, Shinichiro Okamoto et al. · Journal of Thrombosis and Haemostasis · 2012 · 99 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

Masakazu Toi, Hiroji Iwata, Yasuhiro Fujiwara et al. · British Journal of Cancer · 2009 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study

Takumi Kawaguchi, Atsumasa Komori, Masataka Seike et al. · Journal of Gastroenterology · 2012 · 31 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

Hiroji Iwata, Masaru Narabayashi, Yoshinori Ito et al. · International Journal of Clinical Oncology · 2012 · 26 citations

Medicine, Oncology, Pharmacology +17

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study

Shinya Katsutani, Yoshiaki Tomiyama, Akiro Kimura et al. · International Journal of Hematology · 2013 · 25 citations

Medicine, Hematology, Pharmacotherapy +4